glp-1 grocery news shopping shifts as GLP 1 weight loss drugs change diets GLP-1 drugs creating 'seismic shift'

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies and a hypercoagulable state

Protect from UV Light and Heat: Store peptides away from direct sunlight and very warm rooms

p62/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria

The effects of delayed gastric emptying may further compound the risk factors harbored by the obese, diabetic patient: Gastroparesis secondary to diabetes-related autonomic dysfunction Bowel dysmotility from opioids (chronic pain) and prolonged bed-rest Altered oesophageal-gastric anatomy from bariatric surgery Gastric insufflation from overzealous bag-valve ventilation with high PEEP and difficult airway Reduced efficacy of routine antiemetic regime Nausea and vomiting are reported by approximately 50% of patients using GLP-1 agonists, as direct results of reduced gastric motility and activation of central satiety centers

A.HinesR

doi: 10.3748/wjg.15.5871